AcouSort AB Total Liabilities
AcouSort AB total liabilities. Based on the latest financial reports, AcouSort AB (ACOU) has total liabilities worth Skr11.67 Million SEK (≈ $1.26 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of AcouSort AB to measure how many days the company can operate on defensive assets alone.
Total Liabilities of AcouSort AB (2013–2025)
Total liabilities of AcouSort AB from 2013 to 2025. This chart illustrates how AcouSort AB's total liabilities have evolved over time, based on quarterly financial data.
AcouSort AB Competitors by Total Liabilities
The table below lists competitors of AcouSort AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dr. Martens PLC
LSE:DOCS
|
UK | GBX515.80 Million |
|
Liberty Defense Holdings, Ltd. Common Shares
NASDAQ:DETX
|
USA | $4.50 Million |
|
IMAGIS Co. Ltd
KQ:115610
|
Korea | ₩3.45 Billion |
|
Enlitic Inc
AU:ENL
|
Australia | AU$4.24 Million |
|
Vineet Laboratories Limited
NSE:VINEETLAB
|
India | Rs764.24 Million |
|
Synlogic Inc
NASDAQ:SYBX
|
USA | $3.58 Million |
|
Teuza A Fairchild Technology Venture Ltd
TA:TUZA
|
Israel | ILA127.00K |
Liability Composition Analysis (2013–2025)
This chart breaks down AcouSort AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of AcouSort AB.
Liquidity & Leverage Metrics
AcouSort AB Total Liabilities Ratios Explained
AcouSort AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AcouSort AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AcouSort AB (2013–2025)
The table below shows the annual total liabilities of AcouSort AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr1.59 Million ≈ $171.32K |
-58.77% |
| 2024-12-31 | Skr3.86 Million ≈ $415.51K |
-62.80% |
| 2023-12-31 | Skr10.38 Million ≈ $1.12 Million |
-53.96% |
| 2022-12-31 | Skr22.54 Million ≈ $2.43 Million |
+537.14% |
| 2021-12-31 | Skr3.54 Million ≈ $380.75K |
-1.15% |
| 2020-12-31 | Skr3.58 Million ≈ $385.16K |
+69.38% |
| 2019-12-31 | Skr2.11 Million ≈ $227.39K |
+13.60% |
| 2018-12-31 | Skr1.86 Million ≈ $200.17K |
+74.81% |
| 2017-12-31 | Skr1.06 Million ≈ $114.50K |
-48.94% |
| 2016-12-31 | Skr2.08 Million ≈ $224.27K |
+1044.60% |
| 2015-12-31 | Skr182.07K ≈ $19.59K |
-66.51% |
| 2014-12-31 | Skr543.60K ≈ $58.50K |
-74.88% |
| 2013-12-31 | Skr2.16 Million ≈ $232.88K |
-- |
About AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acous… Read more